Innate Pharma (IDD) Stock Overview
Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
IDD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Innate Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.56 |
| 52 Week High | €2.16 |
| 52 Week Low | €1.04 |
| Beta | 0.88 |
| 1 Month Change | -21.80% |
| 3 Month Change | 1.82% |
| 1 Year Change | -12.43% |
| 3 Year Change | -40.42% |
| 5 Year Change | -74.11% |
| Change since IPO | -66.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.5% | -1.5% | -2.3% |
| 1Y | -12.4% | -4.2% | 4.8% |
Return vs Industry: IDD underperformed the German Biotechs industry which returned -2.4% over the past year.
Return vs Market: IDD underperformed the German Market which returned 3.4% over the past year.
Price Volatility
| IDD volatility | |
|---|---|
| IDD Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IDD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IDD's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 164 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
Innate Pharma S.A. Fundamentals Summary
| IDD fundamental statistics | |
|---|---|
| Market cap | €145.39m |
| Earnings (TTM) | -€49.18m |
| Revenue (TTM) | €9.01m |
Is IDD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDD income statement (TTM) | |
|---|---|
| Revenue | €9.01m |
| Cost of Revenue | €43.62m |
| Gross Profit | -€34.61m |
| Other Expenses | €14.56m |
| Earnings | -€49.18m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 17, 2026
| Earnings per share (EPS) | -0.52 |
| Gross Margin | -384.40% |
| Net Profit Margin | -546.11% |
| Debt/Equity Ratio | -102.2% |
How did IDD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/15 06:25 |
| End of Day Share Price | 2026/09/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innate Pharma S.A. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |